Patents by Inventor Nigel C. Phillips

Nigel C. Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7157436
    Abstract: The present invention provides a composition and method comprising a 2–20 base 3?-OH, 5?-OH synthetic oligonucleotide (sequence) selected from the group consisting of (GxTy)n, (TyGx)n, a(GxTy)n, a(TyGx)n, (GxTy)nb, (TyGx)nb, a(GxTy)nb, a(TyGx)nb, wherein x and y is an integer between 1 and 7, n is an integer between 1 and 12, a and b are one or more As, Cs, Gs or Ts and wherein the sequence induces a response selected from the group consisting of induction of cell cycle arrest, inhibition of proliferation, activation of caspases and induction of apoptosis in cancer cells and production of cytokines by immune system cells.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: January 2, 2007
    Assignee: Bioniche Life Sciences, Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 7125858
    Abstract: The present invention relates to a composition and method comprising purified HA, a second anti-neoplastic agent and a pharmaceutically acceptable carrier, wherein the purified HA and the second anti-neoplastic agent are administered to a mammal having cancer in an amount effective to treat the cancer.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: October 24, 2006
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Mario C. Filion, Nigel C. Phillips
  • Patent number: 7087586
    Abstract: The present invention provides compositions comprising a 3?-OH, 5?-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: August 8, 2006
    Assignee: Bioniche Life Sciences, Inc.
    Inventors: Mario C. Filion, Nigel C. Phillips
  • Patent number: 6890911
    Abstract: The present invention relates to a mycobacterial deoxyribonucleic acid (B-DNA) preserved and complexed on the mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the BCC is effective in treating an inflammation in an animal having an inflammation. More particularly, the present invention relates to a Mycobacterium phlei deoxyribonucleic acid (M-DNA) preserved and complexed on Mycobacterium phlei cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the MCC is effective in treating an inflammation in an animal having an inflammation.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: May 10, 2005
    Assignee: Bioniche Life Sciences, Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20040242524
    Abstract: The present invention relates to a composition and method comprising Mycobacterium phlei (M. phlei)-DNA (M-DNA), M-DNA preserved and complexed on M. phlei cell wall (MCC), a chemotherapeutic agent and a pharmaceutically acceptable carrier, wherein the M-DNA and the MCC induce cell cycle arrest in proliferating cancer cells, inhibit proliferation of cancer cells, induce apoptosis in cancer cells and potentiate the antineoplastic effect of the chemotherapeutic agent on cancer cells.
    Type: Application
    Filed: March 23, 2004
    Publication date: December 2, 2004
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 6809081
    Abstract: The present invention relates to a composition and method comprising Mycobacterium phlei (M. phlei)-DNA (M-DNA), M-DNA preserved and complexed on M. phlei cell wall (MCC), a chemotherapeutic agent and a pharmaceutically acceptable carrier, wherein the M-DNA and the MCC induce cell cycle arrest in proliferating cancer cells, inhibit proliferation of cancer cells, induce apoptosis in cancer cells and potentiate the antineoplastic effect of the chemotherapeutic agent on cancer cells.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: October 26, 2004
    Assignee: Bioniche Life Sciences, Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 6794368
    Abstract: The present invention relates to a composition and method useful for regulating cell proliferation and cell death in a multicellular organism. The present invention particularly relates to a composition comprising a bacterial DNA (B-DNA) and a first pharmaceutically acceptable carrier, wherein the B-DNA induces a response in responsive cells of an animal. The present invention more particularly relates to a composition comprising a mycobacterial DNA (M-DNA) and a first pharmaceutically acceptable carrier, wherein the M-DNA inhibits proliferation of responsive cells of an animal, induces apoptosis in responsive cells of an animal, and stimulattes responsive cells of the immune system of an animal to produce bioactive molecules. Methods of making the M-DNA composition and methods of using the M-DNA composition also are disclosed.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: September 21, 2004
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20040058883
    Abstract: The present invention relates to 3′-OH, 5′-OH polynucleotide sequence compositions and methods for activating an immune response in an individual, and more preferably, for activating antigen presenting cells in the individual. In one embodiment, the antigen presenting cell is a dendritic cell. The present invention also includes compositions and methods for activating dendritic cells in vitro. These dendritic cells may then be administered to an individual. Preferred 3′-OH, 5′-OH polynucleotide sequences comprise six bases wherein at least 50% of the bases are guanine and the 5′ base is guanine. The compositions may comprise a phosphodiester or phosphorothioate backbone.
    Type: Application
    Filed: April 22, 2003
    Publication date: March 25, 2004
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20030176381
    Abstract: The present invention relates to a composition and method comprising purified HA, a second anti-neoplastic agent and a pharmaceutically acceptable carrier, wherein the purified HA and the second anti-neoplastic agent are administered to a mammal having cancer in an amount effective to treat the cancer.
    Type: Application
    Filed: August 29, 2002
    Publication date: September 18, 2003
    Inventors: Mario C. Filion, Nigel C. Phillips
  • Publication number: 20030144233
    Abstract: The present invention facilitates in silico evaluation of molecules for biological activity by providing a computer-based method to predict whether oligonucleotides may possess biological activity and the efficacy of the biological activity based on the three-dimensional structure and charge characteristics of the oligonucleotides. Biological activities include, but are not limited to, cellular proliferation, induction of cell cycle arrest and apoptosis.
    Type: Application
    Filed: August 19, 2002
    Publication date: July 31, 2003
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan
  • Publication number: 20030125290
    Abstract: The present invention provides a composition comprising a 5′-OH, 3′-TEG cholesteryl synthetic sequence wherein the sequence is SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8. The present invention provides methods of using this composition for induction of response in a cell, including but not limited to inhibition of cellular proliferation, induction of cell cycle arrest, induction of caspase activation, cleavage of poly(ADP-ribose) polymerase, induction of apoptosis or modulation of extracellular matrix-cell interactions, or combinations thereof, in cancer cells or synovial cells, and methods of using this composition for treating disease.
    Type: Application
    Filed: October 3, 2002
    Publication date: July 3, 2003
    Inventors: Nigel C. Phillips, Mario C. Filion, Andrea C. Herrera Gayol
  • Publication number: 20030119776
    Abstract: A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG)n, (GT)n, a(GT)nb, a(GA)nb, and a(GC)nb, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.
    Type: Application
    Filed: October 25, 2002
    Publication date: June 26, 2003
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20030113763
    Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
    Type: Application
    Filed: August 19, 2002
    Publication date: June 19, 2003
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan
  • Publication number: 20030044352
    Abstract: This invention provides a method for evaluating efficacy of treatment of animals and humans using compositions comprising bacterial DNA and bacterial DNA preserved and complexed on bacterial cell walls. Biological markers such as cytokines, soluble FAS ligand (sFasL) and apoptosis markers released from cells following treatment are measured to assess efficacy of treatment and to identify non-responding patients. This method facilitates identification of animals and humans who should and who should not receive therapeutic administration of these bacterial compositions, and provide a means to evaluate efficacy of such treatment.
    Type: Application
    Filed: April 23, 2002
    Publication date: March 6, 2003
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20030045493
    Abstract: The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.
    Type: Application
    Filed: April 22, 2002
    Publication date: March 6, 2003
    Inventors: Mario C. Filion, Nigel C. Phillips
  • Publication number: 20020091095
    Abstract: A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG)n, (GT)n, a(GT)nb, a(GA)nb, and a(GC)nb, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.
    Type: Application
    Filed: June 12, 2001
    Publication date: July 11, 2002
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 6329347
    Abstract: The present invention relates to a composition and method useful for treating cancer in the urinary bladder. The present invention particularly relates to a composition comprising a Mycobacterium phlei deoxyribonucleic acid (M-DNA)-Mycobacterium phlei cell wall complex (MCC), wherein the M-DNA is preserved and complexed on the Mycobacterium phlei cell wall, and a pharmaceutically acceptable carrier. The MCC composition inhibits proliferation of and induces apoptosis in cancer cells in the urinary bladder and stimulates the responsive cells of the immune system to produce cytokines and reactive oxygen species. Methods of making MCC and methods of using MCC also are disclosed.
    Type: Grant
    Filed: August 5, 1998
    Date of Patent: December 11, 2001
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 6326357
    Abstract: The present invention relates to a composition and method useful for stimulating the immune system and for inhibiting proliferation of and inducing apoptosis in responsive cells of an animal. The present invention further relates to a composition comprising a Mycobacterium phlei deoxyribonucleic acid (M-DNA)-Mycobacterium phlei cell wall complex (MCC), wherein the Mycobacterium phlei-DNA is preserved and complexed on the Mycobacterium phlei cell wall, and a pharmaceutically acceptable carrier. MCC stimulates responsive cells of the immune system to produce cytokines and reactive oxygen species and inhibits proliferation of and induces apoptosis in responsive cells, including cancer cells, in an animal. Methods of making MCC and methods of using MCC also are disclosed.
    Type: Grant
    Filed: August 5, 1998
    Date of Patent: December 4, 2001
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20010041681
    Abstract: The present invention provides a composition and method comprising a 2-20 base 3′-OH, 5′-OH synthetic oligonucleotide (sequence) selected from the group consisting of (GxTy)n, (TyGx)n, a(GxTy)n, a(TyGy)n, (GxTy)nb, (TyGx)nb, a(GxTy)nb, a(TyGx)nb, wherein x and y is an integer between 1 and 7, n is an integer between 1 and 12, a and b are one or more As, Cs, Gs or Ts and wherein the sequence induces a response selected from the group consisting of induction of cell cycle arrest, inhibition of proliferation, activation of caspases and induction of apoptosis in cancer cells and production of cytokines by immune system cells.
    Type: Application
    Filed: December 12, 2000
    Publication date: November 15, 2001
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 6139844
    Abstract: A method for treating or eliminating a protozoal or parasitic disease in an animal in which a sufficient amount of a bacterial cell wall extract is administered to the animal having the protozoal or the parasitic disease. The cell wall extract is preferably a mycobacterial cell wall extract or a cornybacterium cell wall extract. The cell wall extract is most preferably a Mycobacterium phlei cell wall extract.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: October 31, 2000
    Assignee: Bioniche, Inc.
    Inventors: Stanley J. Alkemade, Catherine E. Hildebrand, Nigel C. Phillips, Dragan R. Rogan